ArticleBMC anesthesiology2025
The effect of Dexmedetomidine on remote organ injury in the lung in rats with pancreatic ischemia reperfusion model.
Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Voclosporin ameliorates proteinuria in a model of non-inflammatory glomerular disease.BMC nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPancreatic ischemia-reperfusion (IR) injury can trigger acute lung injury by causing remote organ involvement. Dexmedetomidine has been reported to exhibit antioxidant and cytoprotective effects in various organs. This study aimed to evaluate the protective effects of dexmedetomidine on lung tissue at the histopathological and biochemical levels in an experimental pancreatic IR model.
methodsA total of 24 male Wistar-Albino rats were randomly divided into four groups: Sham, Sham + Dexmedetomidine, Ischemia-Reperfusion (IR), and IR + Dexmedetomidine (IR-D). Pancreatic ischemia was induced in the IR and IR-D groups by clamping the inferior splenic and gastroduodenal arteries. In the dexmedetomidine groups, the drug was administered intraperitoneally. Lung tissues were examined using hematoxylin-eosin staining; neutrophil infiltration, alveolar wall thickness, and total injury score were calculated. Levels of thiobarbituric acid reactive substances (TBARS), enzyme activities of catalase, glutathione-S-transferase (GST), and arylesterase were measured as markers of oxidative stress.
resultsThe IR group exhibited significantly greater neutrophil infiltration/aggregation compared to the Sham group (p = 0.002) and the Sham + Dexmedetomidine group (p = 0.05). Alveolar wall thickness was significantly increased in the IR group compared to both the Sham and Sham + Dexmedetomidine groups (p < 0.001 for both). The total lung injury score was markedly higher in the IR group than in the Sham and Sham + Dexmedetomidine groups (p < 0.001). In the IR-D group, alveolar wall thickness (p = 0.032) and total injury score (p = 0.037) were significantly reduced compared to the IR group. TBARS levels were significantly elevated in the IR group (p = 0.001), while a significant reduction was observed in the IR-D group (p = 0.025). Catalase and arylesterase activities were lower in both IR and IR-D groups compared to the control, but dexmedetomidine significantly increased catalase (p = 0.045) and arylesterase (p = 0.018) activities compared to the IR group.
conclusionDexmedetomidine significantly reduced oxidative stress, alleviated alveolar structural damage, and decreased the total injury score in lung tissue in a pancreatic IR model. These findings suggest that dexmedetomidine may be a potential pharmacological agent for preventing pulmonary complications that can arise following pancreatic surgery or severe pancreatitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.